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Abstract
Background The Contegra® is a conduit made from the bovine
jugular vein and then interposed between the right ventricle and
the pulmonary artery. It is used for cardiac malformations in the
reconstruction of right ventricular outflow tract.
Objective To describe both normal and pathological appear-
ances of the Contegra® in radiological imaging, to describe
imaging of complications and to define the role of CT and
MRI in postoperative follow-up.
Materials and methods Forty-three examinations of 24 patients
(17 boys and 7 girls; mean age: 10.8 years old) with Contegra®
conduits were reviewed. Anatomical description and measure-
ments of the conduits were performed. Pathological items exam-
ined included stenosis, dilatation, plicature or twist, thrombus or
vegetations, calcifications and valvular regurgitation. Findings
were correlated to the echographic gradient through the conduit
when available.
Results CT and MR work-up showed Contegra® stenosis (n=
12), dilatation (n=9) and plicature or twist (n=7). CT displayed
thrombus or vegetations in the Contegra® in three clinically
infected patients. Calcifications of the conduit were present at
CT in 12 patients and valvular regurgitation in three patients. The
comparison between CT and/or MR results showed a good
correlation between the echographic gradient and the presence
of stenosis in the Contegra®.
Conclusion CT and MR bring additional information about
permeability and postoperative anatomy especially when echo-
cardiography is inconclusive. Both techniques depict the normal
appearance of the conduit, and allow comparison and precise
evaluation of changes in the postoperative follow-up.
Keywords Congenital heart disease . Heart valve disease .
Right ventricular outflow tract obstruction . Child
Introduction
Many congenital cardiac malformations are the result of an
abnormal formation of the right ventricular outflow tract
(RVOT). Currently, RVOT reconstruction requires that a conduit
be interposed between the right ventricle and the pulmonary
artery bifurcation [1]. This conduit can be prosthetic (i.e. hetero-
grafts), made of cryopreserved homograft (i.e. cadaveric) or
xenograft tissue. The Contegra®, a pulmonary valved conduit,
represents a commercially available xenograft model.
This conduit is made from the bovine jugular vein, which
naturally contains a tricuspid valve. The valve and its sinus are
located at the middle of the vein. The Contegra® conduit is
suppliedwith or without an external semirigid ring at the valve
annulus. In the United States, the FDA approved its use in
2003. In our institution, we first began implanting the conduit
in 1999. Contegra® implantation is essentially used in con-
genital heart diseases requiring RVOT reconstruction, such
as pulmonary stenosis, pulmonary regurgitation, tetralogy
of Fallot, truncus arteriosus, transposition with ventricular
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septal defect (VSD) and pulmonary atresia, and in the Ross
procedure. It may also replace previously implanted, but dys-
functional, pulmonary homografts or valved conduits [2].
The Contegra® has only been recently used in paediatric
cardiovascular surgery. Clinical and echographic results have
been published from a paediatric cardiologist point of view about
the qualities of the conduit [3–6]. However, as far as we know,
imaging characteristics of normal and pathological valved con-
duits from a radiologist’s point of view have rarely been de-
scribed. In our institution, CTand MRI have won recognition as
appropriate imaging methods before and after Contegra® im-
plantation in various situations: suspicion of conduit stenosis at
echography, follow-up, anatomy evaluation and measurements
of the conduit and of the pulmonary arteries. CT and MRI can
indeed bring relevant additional information to US, and may
prevent or help with planning an invasive procedure.
The purpose of this study was to describe the normal
appearance of a Contegra® conduit using CT and MRI and
to depict early and late complications that may appear in
patients after conduit implantation. We tried to define the role
of CT and MRI not only in the standard follow-up but also in
case of complications.
Materials and methods
The ethical committee was informed about the study but being
a retrospective comparison between two methods, no further
evaluation was required.
Patient population
A search in the radiological database of the department of
radiology between January 1999 and July 2013 showed 24
young patients referred for imaging after Contegra® place-
ment. Inclusion criteria for the study were thorax CT or
cardiac MRI performed in young patients (<25 years) with
Contegra® implantation. We retrospectively reviewed 43 ra-
diological exams (24 CT and 13 MRI) performed on 24
patients (17 males and 7 females). At the time of the radio-
logical examination, mean age and median were 10 years and
8 months and 14 years and 7 months, respectively (range: 1 to
22 years old). Mean time between Contegra® implantation
and imaging was 3 years and 7 months (median: 4 years).
Postoperative follow-up ranged from 1 day to 6 years. The
indications for radiological exams and the main cardiac anom-
alies are listed in Table 1.
Surgical technique
The technique for RVOT reconstruction was the same for all
patients. All Contegra® conduits were rinsed with manual
agitation three times in 500 ml of saline before implantation to
remove glutaraldehyde, which is an element of the manufactur-
ing process. No ring-supported Contegra® conduit was inserted.
The conduits were cut as short as possible to avoid kinking
between proximal and distal anastomosis. The proximal anas-
tomosis was performed in a “hood shape” and the distal section
of the tube was oblique to increase the area of anastomosis in an
attempt to reduce further anastomotic narrowing.
CT protocols
Data were acquired on a 64–detector CT system (Lightspeed
VCT; General Electric Medical System, Milwaukee, USA).
For ECG-gated CT, patients received oral beta blockers 30
to 60 min before the examination. Acquisitions were obtained
after an antecubital intravenous injection of 1.5-2 ml/kg non-
ionic contrast medium (Accupaque 300 or 350; GEHealthcare,
Giles, UK), with 10–20 ml saline solution as bolus chaser.
Helical CT acquisition was started during a single breath hold
when contrast enhancement of at least 200 HU was detected in
the right cavities (bolus tracking). Prospective acquisitions
were preferred for radiation protection reasons. However, they
were mainly performed in older patients and were not always
possible in young children because of their faster heart rates.
When a retrospective acquisition was performed, ECG-gated
axial transverse reconstructions of 1.25-mm slices were obtain-
ed at 10% through 90% at 10% intervals of the R-R cycle. Two-
dimensional reconstructions were always used for measure-
ments and 3-D reconstructions (Advantage Windows worksta-
tion, 4.3, General Electric Medical System, Milwaukee, USA)
were made when necessary.
For non-gated CT, acquisition was made after antecubital
injection of 1.5 to 2 ml/kg of non-ionic contrast medium
(Accupaque 300; GE Healthcare, Giles, UK). Helical acqui-
sition started 25 s after injection or with the Smart prep
technique described above. Breath hold was asked when
possible. Table 2 summarizes the 64-detector row CT proto-
cols that were used with subsequent CT dose index (CTDI)
and dose-length product (DLP) values.
MRI protocols
The cardiac studies were performed on a 1.5-T scanner
(Magnetom Symphony; Siemens, Erlangen, Germany) using
a body coil. MR protocols are summarized in Table 3. The first
sequence was an axial ultrafast spin-echo sequence (HASTE)
covering the entire thorax. Then, cine images were obtained
using ECG-gated multislice gradient echo sequences in various
planes: short axis, 2-chamber view, right ventricular outflow
tract (RVOT), long axis and 4-chamber view. Finally, contrast-
enhanced-MR angiography (CE-MRA) and post-gadolinium
ultrafast gradient echo (VIBE) coronal, axial and sagittal views
were obtained. Depending on the suspicion of pulmonary valve
regurgitation, the examination was completed using velocity-
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Table 1 Patients’ main cardiac anomalies and indication for examination
Patient Age Gender Cardiac anomaly Indication for radiological examination
1 9Y F Aortic valvular stenosis with Ross operation Suspicion of Contegra® stenosis
11Y Control after Contegra® stenting
12Y Control after Contegra® stenting
2 10Y M Tetralogy of Fallot Suspicion of Contegra® stenosis
15Y Evaluation of Contegra® stenosis
15Y Measurements of Contegra® stenosis




4 3Y M Double outlet right ventricle Evaluation of anatomy
5 15Y M Aortic valvular stenosis with Ross operation Suspicion of pulmonary embolism
6 8Y M Pulmonary atresia with ventricular septal defect
(PA-VSD)
Evaluation of anatomy
12Y Measurements of Contegra®
14Y Control after Contegra® stenting
7 7Y F Truncus arteriosus Suspicion of Contegra® stenosis
8 22Y M Pulmonary atresia with ventricular septal defect
(PA-VSD)
Evaluation of anatomy
9 1Y M Double outlet right ventricle Suspicion of pulmonary embolism and assessment of stent
position in the pulmonary artery
10 10Y M Tetralogy of Fallot Assessment of anatomy
10Y Postoperative control
11 12y M Tetralogy of Fallot Assessment of pulmonary vascular anatomy
15Y Follow-up
12 3Y M Tetralogy of Fallot Search for pulmonary oedema or pneumonia
13 2M M Transposition of the Great Arteries (TGA) Assessment of Contegra® , infection
2M Suspicion of endocarditis
4Y Search for remaining septal defect
5Y Suspicion of pulmonary embolism
14 15Y M Aortic valvular stenosis with Ross operation Evaluation of coronary anatomy
15 9Y F Tetralogy of Fallot Postoperative control
16y Pneumonia
16 2y F Tetralogy of Fallot Hemothorax
17 7Y F Tetralogy of Fallot Mediastinitis
18 15Y M Tetralogy of Fallot Suspicion of Contegra® stenosis
15Y Suspicion of Contegra® stenosis
15Y Control after Contegra® stenting
16Y Follow-up
17Y Follow-up
19 16Y M Aortic valvular stenosis with Ross operation Endocarditis
20 17Y F Tetralogy of Fallot Dyspnoea, SVE
21 1Y M Double outlet right ventricle Pulmonary hypertension, suspicion of Contegra® stenosis
22 18Y M Aortic valvular stenosis with Ross operation Retrosternal chest pain unrelated to effort
23 4Y M Tetralogy of Fallot (TOF) Endocarditis
24 2Y M Truncus arteriosus Suspicion of Contegra® stenosis
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encoded cine GRE (phase contrast) sequences. Slice thickness
was 4–8 mmwith a 3-mm gap. Field of view and image matrix
essentially depended on patient size. A double dose, 0.2 mmol/
kg body weight [7, 8], of gadolinium-based contrast material
(Dotarem ® gadoterate meglumine; Guerbet AG, France) was
injected with a mechanical injector pump in an antecubital
intravenous line, followed by 10–20 ml of saline solution. For
the CE-MRA sequence, the bolus detection method (CARE
bolus, Siemens, Erlangen, Germany) was always used. Studies
were performed without anaesthesia, when the patient was old
Table 2 64-detector CT acquisition protocols
Age (year)/weight (kg) 0-1/<10 1-6/10-25 6-12/25-40 >12/>40
Scout view AP+lateral 120 kVp, 10 mA + + + +
Non-gated scan
Gantry rotation time 0.5 0.5 0.5 0.5
Pitch 1.375 1.375 1.375 1.375
Recon. slice thickness (mm) 2.5 2.5 2.5 2.5
Matrix size 512×512 512×512 512×512 512×512
Field of view 180×80 200/200 180/180-250×250 240×240-300×300
kVp/mA 100/120 100/100-450 100-120/180-450 100-120/150-200
CTDIw (mGy) 1.5-2.2 2.6-8 5 5-14
DLP (mGycm) 40 50-190 100-200 200-290
Smart prep 100 kVp/10 mA
CTDIw (mGy)/DLP (mGy) 2.2-3/1.1-1.5 2.5/1.3 3-5/1.5-2.5
Gated scan
Gantry rotation time (s) 0.5 0.5
Pitch 1.375 1.375
Recon. slice thickness (mm) 0.625 0.625
Matrix size 512×512 512×512
Field of view 180×180-250×250 240×240-300×300
kVp/mA 100-120/250-750 100-120/700
CTDIw (mGy) 50 40 70-85
DLP (mGycm) 1,300 855 1,830-2,200
M- M+ M-
M+ with ECG-controlled tube current modulation algorithm (ECG pulsing)
M- without ECG-controlled tube current modulation algorithm
Table 3 MRI protocols
Localizer Ultrafast axial Cine MRI (2, 3 and 4
cavities and RVOT)
CE- MRA Phase contrast (RVOT ) Post-gadolinium sequence
bSSFP HASTE bSSFP FLASH 3-D PC-FLASH FLASH 3-D
Field of view 250 to 300 300 200 to 250 300 300 to 340 300 to 400
Matrix 128×256 128×256 134×208 208×320 192×192 125×320
Breath hold - + + + + +
Cardiac gating - + + + + +
TR/TE (ms) 250/1.3 700/400 43/1.4 3.3/1.1 42/3 4.5/2.2
Flip angle 80 160 80 25 20 10
Slice thickness (mm) 5 5 to 8 4 to 8 0.9 4 to 6 3
Number of signal averages 1 1 1 1 1 1
Acquisition time (s) 20 20 7 — 10 per slice 15 10 s 15 s
RVOT right ventricular outflow tract, CE-MRA contrast-enhanced MR angiography, bSSFP balanced steady-state free precession, HASTE half-Fourier
single-shot turbo spin-echo, PC phase contrast, FLASH fast low angle shot
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enough to cooperate, generally 6 years old if mental status
wasn’t altered. Otherwise, the studies were done under general
anaesthesia with intubation to obtain apnoea on demand.
The choice between CT and MRI was based on emergency
level and the clinicians’ interest about Contegra® calcification.
MR was preferred in functional studies. CT was generally avail-
able more quickly. It is interesting to point out that no ECG-gated
CTwas performedonpatients younger than 6 years of age because
of concerns about radiation doses.
Image analysis
The CTandMR images were evaluated separately by two radiol-
ogists (F.G. and E.T.), who were blinded to the results of other
imaging studies (US). In case of disagreement, final results were
obtained by consensus between the two radiologists (F.G., 6 years
experience and E.T., fellow with less than 1 year experience). The
images were viewed on a workstation (Advantage windows soft-
ware 4.3; GE Medical System, Milwaukee, USA) using 2-D
(MIP, MPR) and 3-D (VR) reconstructions. Afterward, results
were discussed with the paediatric cardiologists and paediatric
cardiovascular surgeons.
The following imaging findings were reviewed:
In normal conduits: shape, diameter, length, wall thick-
ness and wall calcifications, patency.
In abnormal conduits: stenosis, dilatation, plicature or
twist of the conduit, thrombus, calcifications and valvular
regurgitation.
Each itemwas evaluated in every radiological study, rated in a
binary mode (present or absent) according to the findings. Ste-
nosis, dilatation, plicature or twist and thrombus were assessed
on CT and MR images. Although they were sometimes visible
withMRI, we decided that calcificationsweremuchmore visible
on CT and could only be evaluated with confidence using CT
images. For obvious reasons, valvular regurgitation was only
assessed with MR images.
To define the dilatation or stenosis of the Contegra®, we
considered as significant the values that were larger or smaller
than 50% of the initial internal diameter of the conduit at the time
of implantation. Both the smallest and the largest diameters of the
conduit were measured, using reconstructions of cross-sectional
planes on 3-D MR gadolinium-enhanced sequences [8].
Results
All patients underwent CT and MR without complications.
Imaging findings are listed in Table 4.
A normal, recently implanted conduit appears as a thin-
walled conduit binding the RVOT to the pulmonary trunk or
one of its branches. The calibre is the same all along the conduit
and corresponds to the diametermeasured before implantation and
given by the manufacturer. Graft walls are smooth and regular
(Fig. 1). They are hypodense onCTand slightly thicker than those
of the vessel towhich they are anastomosed.Occasionally, surgical
clips can be seen at both extremities and should not be confused
with calcifications. Normal valve leaflets are not always visible,
especially on MR. On CT, they can be depicted if they are closed
during the acquisition time, which may be the case in CTs
performed without gating or with a prospective ECG-gating [9].
Valves are sometimes detectable as thin, regular and symmetrical
lines, forming the classical Mercedes-Benz® emblem on axial
views.
Twelve gated CTs and 15 non-gated CTs were performed.
Eight of the gated CTs were done with a retrospective ECG-
gating and four were done with a prospective ECG-gating.
In six patients, a normal Contegra® was depicted at least
once (patients 3, 10, 11, 16, 20, 22). In the others, no abnormal
findings were depicted. However, they were not considered
normal because a valve or a stent had been implanted inside.
With CT, the Contegra® is more clearly depicted with gated
acquisitions. In non-gated acquisitions, cardiac movement arte-
facts are always present, but they never prevent the readers from
assessing the defined items.
With MR, the acquisition is always gated. Then, only the
lower spatial resolution prevents from seeing the valve leaflets
and the conduit’s wall. However, like with CT, it is always
possible to evaluate the defined items.
The complications are analysed separately. They are sum-
marized in Table 5.
The number of patients per complication is larger than the
number of patients included in this study because the same patient
can have more than one complication. In the 43 examinations, 17
showed no complications of the Contegra and 26 showed at least
one complication. The 17 normal studies concerned 12 different
patients. Those patients had radiological exams for follow-up
(insufficient echogenicity) or as a baseline imaging after the
insertion of a new Contegra.
Calcifications of the conduit were found in 11CTexaminations
in 11 patients. Hence, 46% of the patients having a CT in their
medical records had a calcified Contegra®. In patients with a
calcified Contegra®, the conduit had been in position for at least
1.5 years (mean time: 5 years) (Fig. 2). In our five patients with a
previous endocarditis, four had a calcified Contegra®. The one
without calcification was suspected of a previous endocarditis, but
it was never proved. Calcifications were responsible for a signif-
icant stenosis in only four patients.
Stenosis of the conduit were found in 10 patients (41.7%)
among 43 examinations. Generally, the stenosis had the follow-
ing causes: plicature or twist of the Contegra® (two patients),
calcifications (four patients) or parietal thickening due to known
or suspected endocarditis (four patients). In three patients, the
stenosis was associated with valvular regurgitation. Ultrasound
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Table 4 Imaging findings
Patient Age Gender Age of
Contegra®
Echocardiographic
gradient in mm Hg
CT findings MR findings
Stenosis, dilatation, plicature/ twist,
thrombus/vegetations, calcification
Stenosis, dilatation, plicature/ twist, thrombus/
vegetations, valvular regurgitation
1 9Y F 4Y 70 Stenosis
11Y 6Y 11.3 None
12Y 7Y 20 None
2 10Y M 5Y 50 Stenosis and valvular regurgitation
15Y 10Y 50 Stenosis and valvular regurgitation
15Y 10Y NA Stenosis and calcification
3 15Y F 4Y 15 None
16Y 5Y NA None
17Y 6Y 23 None
18Y 7Y 16 None
4 3Y M 2Y 21 None
5 15Y M 5Y 90 Stenosis
6 8Y M 6Y 37 Stenosis, dilatation and valvular regurgitation
12Y 9Y 60 Stenosis, dilatation and valvular regurgitation
14Y 11Y 25 None
7 7Y F 7Y 60 Calcifications
8 22Y M 10Y NA Calcifications
9 1Y M 1Y 60 None
10 10Y M 4Y 70 Calcifications
10Y 10D 35 None
11 12y M 6M 37 None
15Y 2Y NA Calcifications
12 3Y M 1M 10 Plicature/twist
13 2Y M 7M 60 Dilatation
2Y 9M 60 Dilatation
4Y 3Y 60 Stenosis and dilatation
5Y 10D 8 None
14 15Y M 4Y 25 Calcifications
15 9Y F 1M 60 Plicature/twist
16y 6Y 110 Stenosis, plicature/twist and calcifications
16 2y F 5D 12 None
17 7Y F 5Y 50 Dilatation, thrombus/vegetation and
calcifications
18 15Y M 1M 75 Stenosis and plicature/twist
15Y 1M 28 Stenosis, plicature/twist
15Y 1M 31 None
16Y 5M 34 None
17Y 2Y 19 Calcifications
19 16Y M 1.5Y 60 Stenosis, thrombus/vegetation and
calcifications
20 17Y F 7Y 27 None
21 1Y M 2M NA Stenosis and plicature/twist
22 18Y M 2.5y NA None
23 4Y M 4Y 90 Stenosis, dilatation and calcifications
24 2Y M 2.5Y 50 Stenosis, dilatation and valvular regurgitation
NA not available
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values were available for almost all patients. At echocardiogra-
phy, the gradient through the conduit was considered significant
if it was equal to or more than 50 mmHg. Patients with a visible
stenosis on MR or CT always showed a significantly elevated
gradient on US. The discrepancy between echography and CT
for patient 18 is explained by the fact that the CTwas performed
just before reintervention and the echography right after
reintervention. As for patient 6, the first echographic gradient
was measured at 37 mmHg. A stenosis of the conduit was
described on the MRI, but it was close to 50% and considered
not significant at that time. The stenoses were often located at
both extremities of the conduit (6/10 cases) except if secondary
to infection (4/10 cases). In those cases, the stenosis was more
global, due to parietal thickening caused by infection.
In two cases reported by Kadner et al. [10], the early
apparition of stenosis was probably promoted by the presence
of hypoplastic pulmonary arteries at the distal anastomosis of
the conduit and by conduits of small calibre, which caused a
disadvantageous turbulent flow pattern. We encountered a
similar case in a patient with a twisted right pulmonary artery
Fig. 1 CT and MR images of a
normal Contegra® in patient 11. a
CT sagittal MIP view shows the
normal appearance of the
Contegra®. Note the hardly
depictable normal valve leaflets
(arrow). b CT 3-D VR
reconstruction shows a
Contegra® with normal CT
appearance. c Contrast-enhanced
CTwith axial MIP view shows a
normal Contegra® with surgical
clips at both extremities (arrows).
d MRA, sagittal view, shows the
normal MR appearance of a
Contegra®. The valve leaflets are
not visible
Table 5 Type and number of complication with Contegra® and patient’s age
Mean patient’s age (range) Mean Contegra®’s age (range) Type of complications Number of complications
(% of exams)
Number of patients per
complication (% of
patients)
10.5 years (1 year-16 years) 3.8 years (1 month-10 years) Stenosis 15 (55.6%) 10 (41.7%)
5.1 years (2 years-12 years) 3.9 years (1 month-9 years) Dilatation 8 (30%) 5 (20.8%)
4.7 years (1 month-16 years) 1.1 years (1 month-6 years) Plicature/twist 6 (22.2%) 4 (16.6%)
11.5 years (7 years-16 years) 3.3 years (1.5 years-5 years) Thrombus/vegetations 2 (7.4%) 2 (8.3%)
13.1 years (4 years-22 years) 5 years (1.5 years-10 years) Calcifications 11 (40.7%) 11 (45.8%)
6.4 years (2 years-10 years) 6.5 years (2.5 years-10 years) Valvular regurgitation 5 (18.5%) 3 (12.5%)
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who developed a severe stenosis of the distal Contegra®
(Fig. 3).
A dilated Contegra® was found in five patients (20.8%)
(Fig. 4). It was associated with the presence of proximal
stenosis in three cases and with post-infectious changes
resulting from a healed endocarditis in the three others.
Plicature of the conduit was found in four cases (16.7%). It
was visible as a gathered aspect of the conduit’s walls. Two of
the patients presented with severe stenosis. The first one
showed a hypoplasia of the left pulmonary arteries (Fig. 5)
and the second one had a conduit placed in an extra-
anatomical location, causing the twist (Fig. 6).
Vegetations and thrombus on the Contegra® valve were
seen in two CT examinations. The first had been referred for
imaging on suspicion of pulmonary embolism and the second
for mediastinitis, both in an infectious context. Intraluminal
thrombus of the conduit appeared as a hypodense parietal
thickening. Vegetations were noticeable as a focal hypodense
thickening of the valve leaflets (Fig. 7).
Significant valvular regurgitation was found in five MR
exams (three patients), always confirming the diagnosis first
made at echography.
A comparison between echographic gradient and MR or
CT findings showed a good correlation between both tech-
niques to evaluate the Contegra® lumen reduction. In patients
with a gradient equal or superior to 60 mmHg on echography,
the Contegra® was almost always stenosed or calcified (80%
of the cases). In two cases, a gradient superior to 60 mmHg
was found on echography, but no clear stenosis of the
Contegra® could be depicted on CT (patients 9 and 13). For
patient 9, the gradient was 60 mmHg and no stenosis of the
Contegra® was visible. However, this patient had a stenosis of
a pulmonary artery. After stenting of this artery, the gradient
returned to normal. Case number 13 had a dilated but not
really stenosed Contegra®. The significant echographic gra-
dient probably was explained by vegetations that were visible
only with US.
In our study, nine patients underwent cardiac catheteriza-
tion. In seven cases, the reason was the implantation of a new
valve (five patients)/stent (one patient) in the Contegra® or in
a pulmonary artery (one patient). For the two remaining
patients, angiocardiograms were performed as a preoperative
assessment, one after CTand one after MRI. For those studies,
results were concordant.
Discussion
During the last decade, various prosthetic conduits have been
used for the reconstruction of RVOT in congenital cardiac
anomalies. The Contegra® valved conduit is one of them. It is
available in all sizes between 12 and 22 mm of internal
diameter, something that constitutes a major advantage over
homografts, especially for paediatric patients who require
small diameter conduits. Short-term results have shown prom-
ising results with Contegra® compared to other xenografts [6,
11]. After implantation, the first evaluation is generally made
using echography. However CT and MRI have become in-
creasingly used in both the immediate postoperative assess-
ment and in the long-term follow-up of congenital cardiac
malformations [8, 12]. Nonetheless, as far as we know, the
radiological appearance (with CT and MR) of the normal
Contegra® and its specific complications have never been
described. With this study, we hope to define the normal
imaging of the Contegra® conduit and to describe important
items that should be examined in the work-up of these
patients.
In our institution, CT and MRI are additional imaging
methods, never performed before echography. Both
Fig. 2 CT with MIP reconstruction (sagittal view) shows a severely
calcified Contegra® 7 years after insertion in patient 7
Fig. 3 Stenosis at the distal extremity of the Contegra® in patient 21.
Axial contrast-enhanced CT shows the stenosed distal extremity of the
conduit (arrow) and a twisted right pulmonary artery (arrowhead)
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techniques are less invasive than transoesophageal echography
or arteriography and are not operator-dependent. Generally, CT
and MR are requested by the paediatric cardiologists or the
cardiovascular surgeon to answer a specific question
concerning measurements and anatomy or to confirm a
suspected complication such as pulmonary embolism, endocar-
ditis or pulmonary regurgitation. Both studies appear to be very
helpful before and after an endovascular procedure, especially
when echocardiography is suboptimal due to patient anatomy
or postoperative changes. However, it is always important to
discuss the position of the conduit with the surgeons because
different implantation techniques exist depending on the type of
cardiac malformation and the patient anatomy.
In an initial assessment, CT and MRI may bring additional
information about coexisting pathologies and concomitant
anomalies, displaying the pulmonary vessels and the aorta.
For example, in one of our cases, a CT performed to assess
endocarditis complications showed not only a Contegra®
stenosis with valvular leaflet thickening but also a pulmonary
embolism (case 17).
In follow-up studies, CT and MRI enable an objective
comparison of various examinations of the same patient.
Fig. 4 A dilated Contegra® with
stenosis at both extremities in
patient 6. aMRA axial MIP view
shows the stenosis at both
extremities of the Contegra®
(arrows) b Reconstruction of a
contrast-enhanced CT shows the
dilatation in the middle of the
Contegra® (arrow). Coronal (c)
and (d) sagittal arteriography
views confirm the finding on CT
Fig. 5 A twisted Contegra® in a
patient with a hypoplastic left
pulmonary artery in patient 12. a
Axial contrast-enhanced CT
depicts the plicature (arrow). b 3-
D VR reconstruction of the
contrast-enhanced CT shows the
kinked Contegra® (arrow)
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CT provides images of excellent spatial resolution in a fast
acquisition time and it is generally available quickly. Some-
times, exact localization of the stenosis site can be difficult
with echography, because of the small distance between the
conduit valve and the pulmonary artery bifurcation [13]. In
those cases, CT proves to be of significant help. It is increas-
ingly preferred to catheter angiography, also because it offers
3-D volume data in a noninvasive way. Consequently, a well-
conducted CTexamination may delay or replace angiography.
Nevertheless, high radiation doses and contrast medium caus-
ing kidney burden are the major drawbacks of CT [14]. In our
institution, ECG-gated CTs are done in a retrospective mode,
only when a high cardiac frequency precludes prospective
acquisitions. In general, beta-blockers are used to lower and
stabilize the heart rate. When cardiac rhythm remains stable
between 55 and 75 bpm, a prospective acquisition is selected.
Otherwise, we choose retrospective acquisition. Gated CT is
performed only when depiction of small structures, such as the
coronary arteries, is necessary. Usually, if the question in-
volves great vessel anatomy and Contegra® permeability, a
non-gated CT is considered sufficient. With gated CT, the
major benefit was a clear depiction of the RVOT walls,
Fig. 6 Twisted Contegra® in
patient 18. a Contrast-enhanced
CTwith VR reconstruction shows
the twisted Contegra® placed in
an extra-anatomical location
because of an aberrant coronary
origin. b Contrast-enhanced CT
with oblique MIP view shows the
twisted Contegra®. c VR
reconstruction of a contrast-
enhanced CT shows the twisted
Contegra® after stenting. d
Oblique MIP view of a contrast-
enhanced CT shows the stent in
the twisted Contegra® (arrow)
Fig. 7 Endocarditis with mediastinitis in patient 17. aContrast-enhanced
CTwith sagittal MIP view shows the thickened valve leaflets (arrow). b
Axial oblique MPR reconstruction of a contrast-enhanced CT shows the
mediastinal collection surrounding the Contegra® (arrows). c Axial view
of a contrast-enhanced CT shows the parietal enhancement of the collec-
tion (arrows)
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without motion artefacts. Gating was helpful in measuring the
true lumen of the Contegra® and avoided over- or underesti-
mation of a potential stenosis. However, this is a retrospective
study up to 1999, at the beginning of cardiac CT. It explains
the important DLP values obtained for gated CT, especially
the retrospective ones. Up-to-date recommendations state that
in the paediatric population, cardiac CT should now be ac-
quired at 80 or even 70 kV. Prospective imaging should also
be favoured. If retrospective CT is performed, it should be
acquired with a monophasic acquisition, preferentially at sys-
tolic phase to decrease motion artefacts. This significantly
reduces the radiation dose [15].
MRI is a noninvasive non-ionising technique, valuable for
functional and anatomical evaluation. In addition, in case of
valve failure, MRI might provide more reliable data on val-
vular regurgitation and ventricle volumes than echography.
MRI is also valuable for planning catheter-guided interven-
tions [16]. Nonetheless, it is less easily available and more
expensive than CT or echography. It is also time-consuming
and always requires sedation.
Previous studies have reported that the bovine jugular graft
was free of calcification even several years after implantation
[3, 4, 17]. Breymann et al. [4] describedmild calcifications after
a 5-year follow-up using standardised echocardiography, in
only 8 examinations out of 165 patients. However, we were
surprised to find an important number of calcified conduits
(42% of CT examinations), some of them being severely af-
fected only 2.5 years after implantation. This may be because of
the selection bias present in our study because cardiologists had
mostly referred patients with bad evolution for additional im-
aging studies and because CT is probably more sensitive than
echography in the detection of conduit wall calcifications.
In our series, four CTexams and one MR showed a twisted
Contegra®. BothMR and CTwere able to depict a plicature of
the Contegra® (patient 18). However, plicatures have rarely
been described in the literature. To our knowledge, the only
mention of a twisted Contegra® comes from Corno et al. [17].
CT and MR allow detection and precise measurements of
stenosis. For Shoenhoff and coworkers [11], the first cause
of graft failure was progressive stenosis with frequent forma-
tion of a stenotic membrane at the distal anastomosis. Other
reports also emphasized the presence of stenosis at the pul-
monary anastomosis imputed to excessive intimal peel forma-
tion and perigraft scarring [18, 19].
We also found two patients with a stenosed conduit after a
Ross operation for aortic stenosis, even if this type of proce-
dure is said to carry less risk of Contegra® stenosis. The lower
risk is attributed to the fact that, in patients with aortic stenosis,
the pulmonary arteries are normal and the conduit is larger [4].
For Iyer [20], the wall of the Contegra® tends to be thicker
than the wall of the native pulmonary arteries causing a
difficulty in anastomosing them. This could also lead to early
distal stenosis.
Another factor that can be associated with early stenosis of
the Contegra® is an insufficient rinsing of the conduit before
implantation: Remnants of glutaraldehyde storage solution
could indeed accelerate stenosis [4].
Gradient elevation inside the conduit was found in case of
pulmonary embolism or significant lumen reduction of the
Contegra® at CT or MRI and showed a good correlation with
echographic findings. However, in young or restless children,
the echographic gradient can be overestimated when the child
is not sedated. For this reason, it is always important to be
aware of the exam conditions when there is a discrepancy
between echography and the other modalities.
The association between the presence of isolated calcifica-
tions and a high echographic gradient could not be demon-
strated. Then, even if calcifications were frequently noted,
they were rarely responsible for a significant stenosis when
isolated.
A few cases of aneurysmal dilatation of the Contegra®
have been described in the literature [21]. The dilatation can
be limited to the sites of anastomosis [13, 22] or it can concern
the entire conduit [23]. In our cohort, we found some dilated
conduits, but the dilatation was always associated with imme-
diate proximal stenosis, if not due to infection. The most
striking case was a string-of-beads stenosis with a succession
of stenosis and dilatations. We then considered that dilatations
of the conduit were mainly the result of pre-existing stenosis.
Infection is a major risk factor for the early aging of the
conduit. The patients with history of endocarditis presented
with a severely distorted Contegra® such as a thickened valve
leaflet, inspissated conduit walls and parietal calcifications.
Those changes were principally detected with CT studies in
our series. CT and MRI are also valuable when infection is
suspected because they clearly depict mediastinal collections
in cases of superimposed mediastinitis (Fig. 8). Tiete [13]
reported a patient with a fibrinous membrane inside the
Contegra®, most likely caused by thrombus formation that
could be peeled off from the conduit wall. We found a similar
case (patient 19) presenting with endocarditis where CT also
depicted a membrane that was subsequently confirmed at
Fig. 8 Endocarditis in patient 19. Cardiac-gated CT, sagittal view, shows
a hypodense membrane inside the Contegra® (arrow)
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echography and that could correspond to a fibrinous mem-
brane (Fig. 8).
One advantage of the Contegra® conduits resides in its
high pliability [13, 18]. Yet, it can also prove to be a serious
inconvenience in certain circumstances. In our series,
plicature or even complete twist of the conduit could be seen
on 3-D VR reconstructions in four patients. This finding
provided an explanation for the appearance of early stenosis,
which, in fact, was due to the morphology of the conduit and
not to parietal changes. In each of these four patients, the
twisted and plicatured Contegra® was ascribed to severe
stenosis of the pulmonary arteries or to difficulties at the time
of implantation.
Valvular regurgitation was confirmed by MR in two pa-
tients. This complication is classical and has been prospec-
tively studied by Nordmeyer et al. [24] in homografts inserted
in the pulmonary position. For Nordmeyer, homograft distor-
tion is linked to a negative functional outcome. In our patients,
conduits with an insufficient valve were not twisted but mark-
edly stenosed.
Valve insertion in the event of valve failure or implantation
of a stent in case of conduit stenosis constitutes major progress
compared to immediate graft replacement. Chronic right ven-
tricle overload is associated with dysfunction and sudden
death. Percutaneous pulmonary valve implantation improves
RVOT hemodynamic and delays surgery by prolonging the
conduit lifespan [25]. Procedural results are excellent with a
6% procedural complication rate in specialized centres. For
Lurz et al. [26] the major complication is stent fractures (20%
of the cases) warranting close surveillance and sometimes
second device insertion. CT and angio-MR enable accurate
planning before catheter intervention [16]. For example, our
patient 10 had a stenosed valve, visible on CT by the presence
of thin calcifications involving the valvular leaflets. After
implantation of a Sapien® valve, the echographic gradient
returned to normal (Fig. 9). In another example of a twisted
Contegra® (patient 18), the conduit had been inserted in an
unusual location because of an anomalous right coronary
artery origin: The conduit had been implanted inside the
native pulmonary trunk instead of in an extracardiac position.
CT images showedwell the extremely twisted conduit causing
a significant stenosis of the lumen (Fig. 5). After stenting, the
echographic gradient lowered from 75 to 28 mmHg and CT
showed no residual stenosis. Furthermore, it is interesting to
note that the twist is displayed much easier in 3-D MPR
reconstructions.
In our series, factors associated with early aging of the
conduit and likely to cause complications, such as endocardi-
tis, size of the pulmonary vessels, type of anastomosis and
implantation techniques, were well depicted by both CT and
MR. Some other factors, also causing conduit aging, are not
visible with imaging: the suturing technique, intraoperative
handling of the Contegra® and selection of size. For all its
limitations, the Contegra® is not always the conduit of choice
for many surgeons [20]. However, as long as nothing better is
found, the paediatric radiologist will be confronted with the
imaging of those conduits. When evaluating those conduits,
the radiologist has to keep in mind that the best modality to
depict twist or calcifications is CT and that MR is the gold
standard for flow and ventricular function measurements.
This study has some limitations. First, it is a retrospective
study with a heterogeneous group of patients and examina-
tions. Secondly, it deliberately concentrates on one type of
conduit, the Contegra®, putting aside homografts, xenografts
and other prosthetic conduits. There is also a selection bias, as
the patients referred for additional imaging work-up were
generally those with suspected complications. This fact ex-
plains the discrepancies with results of other studies in terms
Fig. 9 Two different patients
with a valve inserted inside the
Contegra®. a CTwith sagittal
view shows a Sapien® valve
(arrow) implanted in a previously
stenosed Contegra® in patient 10.
bMR steady-state fast precession
sagittal view shows a Sapien®
valve implanted in a previously
stenosed Contegra® in patient 1.
Note the artefacts caused by the
valve (arrow)
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of complication rates. As the study is retrospective, hemody-
namic values of the valve were not routinely assessed with
MR at that time. In the future, it would be interesting to
compare CT and MR. This would be possible only in a
prospective study. Finally, as the Contegra® is a biological
conduit, it is not yet possible to know if every conduit has the
same physical and aging properties.
Conclusion
The quick availability and great accessibility has made CT an
essential imaging technique when assessing congenital heart
disease. It enables the acquisition of high spatial resolution
images in a short scanning time, generally avoiding sedation.
Likewise, MRI has become of prime importance when eval-
uating cardiac function and flow measurements. After
Contegra® implantation, there are benefits to using both tech-
niques. Even if echography remains the primary imaging
study, if it is inconclusive, CT and MR bring additional
information about permeability and postoperative anatomy.
They make it possible to depict the normal radiological ap-
pearance of the conduit, and allow comparison and a precise
evaluation of any changes in the follow-up period. In the
search for complications, they clearly identify stenosis and
dilatations, which should always be described compared to the
original diameter of the conduit, i.e. before implantation.
Calcifications and fibrous membranes are also more visible
compared to echography. Evaluation of pulmonary vessels
distal to the conduit is made much easier. In addition, 3-D
andMPR reconstructions seem to be helpful in assessing graft
twist. Moreover, CT is highly sensible in showing calcifica-
tion and valve leaflets thickening occurring after endocarditis.
Finally, 2-D and 3-D reconstructions are very helpful in plan-
ning catheter-guided interventions in case of valve implanta-
tion or Contegra® stenting. The capacity of MR and CT
imaging to precisely depict the position of the stent or the
newly implanted valve is highly valuable during the postop-
erative period.
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